药明生物在安全审查中表现出信心

尽管美国立法提出了安全担忧，但中国合同开发商和制造商药明生物仍然保持乐观。该公司预计 2024 年将实现增长，理由是人口老龄化和慢性病流行导致对生物制剂的需求增加。药明生物将其重点放在端到端服务上，吸引了大型生物制药公司和小型生物技术公司。

WuXi Biologics Exudes Confidence Amid National Security Concerns

国家安全忧虑下，药明生物信心十足

WuXi Biologics, a leading Chinese contract research, development, and manufacturing (CDMO) firm, has expressed optimism for 2024, following a similar upbeat forecast from its parent company, WuXi AppTec. The company maintains a bullish outlook despite headwinds and national security concerns in the United States.

继其母公司药明康德也做出了类似的乐观预测之后，中国领先的合同研究、开发和制造 (CDMO) 公司药明生物也对 2024 年表示乐观。尽管面临美国的不利因素和国家安全担忧，该公司仍保持乐观的前景。

In its financial results announced on Tuesday, WuXi Biologics reported a revenue increase of 11.6% year-over-year to RMB 17.03 billion (approximately $2.4 billion). The company attributes its positive outlook to its focus on biologics, which are in growing demand due to an aging population and rising incidence of chronic diseases.

在周二公布的财务业绩中，药明生物营收同比增长 11.6%，达到 170.3 亿元人民币（约合 24 亿美元）。该公司将其积极的前景归因于对生物制剂的关注，由于人口老龄化和慢性病发病率上升，生物制剂的需求不断增长。

WuXi highlights the increasing reliance of large biopharma companies on CDMOs for cost reduction and efficiency gains. Small and medium-sized biotech companies also depend on CDMOs to advance their projects due to their limited in-house R&D and production capabilities.

药明康德强调，大型生物制药公司越来越依赖 CDMO 来降低成本和提高效率。中小型生物技术公司由于内部研发和生产能力有限，也依赖 CDMO 来推进项目。

The company's non-COVID business exhibited a robust 37.7% revenue increase, while late-phase and commercial manufacturing revenue surged to RMB 7.73 billion, accounting for 45.5% of total sales in 2023. WuXi's integrated end-to-end platform for contract research, development, and manufacturing positions it well for "sustainable growth," as stated in its financial report.

该公司的非新冠业务收入强劲增长37.7%，而后期和商业制造收入飙升至人民币77.3亿元，占2023年总销售额的45.5%。药明康德的集成端到端合同研究平台，正如其财务报告所述，开发和制造使其处于“可持续增长”的有利位置。

However, WuXi Biologics' optimism is tempered by potential threats from U.S. legislation. The proposed BIOSECURE Act, introduced in January, has designated WuXi Biologics and WuXi AppTec as "foreign adversary biotech companies of U.S. national security concern." The legislation aims to prevent federal funding from supporting these companies, amidst concerns that they could provide sensitive data to Chinese authorities.

然而，药明生物的乐观情绪因美国立法的潜在威胁而受到影响。今年 1 月推出的《BIOSECURE 法案》将药明生物和药明康德指定为“对美国国家安全构成威胁的外国对手生物技术公司”。该立法旨在阻止联邦资金支持这些公司，因为担心它们可能向中国当局提供敏感数据。

WuXi Biologics has vigorously defended itself against these allegations, stating that the bill contains a "misleading description" of its CEO, Dr. Zhisheng Chen. The company has pledged to uphold the highest standards of compliance and abide by all applicable laws and regulations.

药明生物针对这些指控进行了积极的辩护，称该法案包含对其首席执行官陈志胜博士的“误导性描述”。该公司承诺维护最高的合规标准并遵守所有适用的法律和法规。

Despite the recent departure of Rep. Mike Gallagher, a Republican sponsor of the BIOSECURE Act, the legislation's future remains uncertain. Nonetheless, WuXi Biologics' stock price has yet to recover from the significant declines witnessed earlier this year, down approximately 50% year-to-date.

尽管《生物安全法案》的共和党发起人、众议员迈克·加拉格尔 (Mike Gallagher) 最近离职，但该法案的未来仍然不确定。尽管如此，药明生物的股价尚未从今年早些时候的大幅下跌中恢复过来，今年迄今已下跌约 50%。

Similarly, WuXi AppTec has expressed confidence for the remainder of 2024, expecting revenue growth and the execution of planned expansion projects, despite the legislative threats. The company's optimistic outlook highlights the continued demand for outsourced biopharmaceutical services, despite geopolitical tensions.

同样，尽管面临立法威胁，药明康德也对 2024 年剩余时间表达了信心，预计收入增长并执行计划的扩张项目。尽管地缘政治紧张，该公司的乐观前景凸显了对外包生物制药服务的持续需求。